Suppr超能文献

急诊科肌内注射奥氮平与胃肠外给予苯二氮䓬类药物联合使用的回顾性研究。

A retrospective review of intramuscular olanzapine and parenteral benzodiazepine coadministration in the emergency department.

作者信息

Laub Jessica, Treu Cierra N, Takamura Kei, Mendoza Christopher

机构信息

Clinical Pharmacist, Department of Pharmacy, Ralph H. Johnson VA Medical Center, Charleston, South Carolina.

Director of Clinical Informatics, Department of Data Management, NYC Health + Hospitals/South Brooklyn Health, Brooklyn, New York.

出版信息

Ment Health Clin. 2024 Oct 1;14(5):280-285. doi: 10.9740/mhc.2024.10.280. eCollection 2024 Oct.

Abstract

INTRODUCTION

Acute agitation is a common presenting symptom in medical and mental health emergencies that may require pharmacologic intervention. There is a manufacturer recommendation against intramuscular coadministration of olanzapine with parenteral (intramuscular or intravenous) benzodiazepines despite a deficiency of high-quality evidence. The purpose of this study was to contribute to available literature regarding intramuscular olanzapine and parenteral benzodiazepine use in acutely agitated patients in the emergency department (ED).

METHODS

This was a single-center retrospective chart review of adult ED patients who received intramuscular olanzapine and a parenteral benzodiazepine within 2 hours. The composite primary endpoint evaluated the occurrence of cardiac or respiratory compromise within 2 hours of medication administration. Secondary endpoints mirrored the primary endpoint within 30 minutes and evaluated the occurrence of cardiac arrest or desaturation in the ED outside the 2-hour window.

RESULTS

One hundred eleven patients were included in the analysis, 64 (57.7%) of whom had documented vitals or oxygen status within 2 hours of medication administration. The composite primary endpoint occurred in 8 patients (12.5%), with only 1 patient requiring intervention with intravenous fluids. The secondary composite endpoint occurred in 2 (9.5%) of 21 patients with documented vitals or oxygen status within 30 minutes of treatment, neither of which required intervention. There were no identified events of intubation or significant cardiac events.

DISCUSSION

Until better evidence is available, this combination therapy should, at minimum, include appropriate patient monitoring. Future studies should investigate risk factors for serious adverse effects.

摘要

引言

急性激越在医疗和心理健康紧急情况中是常见的症状,可能需要药物干预。尽管缺乏高质量证据,但药品制造商建议不要将奥氮平与肠外(肌内或静脉)苯二氮䓬类药物联合肌内注射。本研究的目的是为急诊科(ED)急性激越患者使用肌内注射奥氮平和肠外苯二氮䓬类药物的现有文献提供补充。

方法

这是一项对在2小时内接受肌内注射奥氮平和肠外苯二氮䓬类药物的成年ED患者进行的单中心回顾性病历审查。复合主要终点评估给药后2小时内心脏或呼吸功能受损的发生情况。次要终点反映给药后30分钟内的主要终点,并评估在2小时时间段之外的急诊科内心脏骤停或血氧饱和度降低的发生情况。

结果

111名患者纳入分析,其中64名(57.7%)在给药后2小时内记录了生命体征或氧状态。复合主要终点在8名患者(12.5%)中出现,仅1名患者需要静脉输液干预。在治疗后30分钟内记录了生命体征或氧状态的21名患者中,次要复合终点在2名(9.5%)患者中出现,均无需干预。未发现插管事件或重大心脏事件。

讨论

在获得更好的证据之前,这种联合治疗至少应包括适当的患者监测。未来的研究应调查严重不良反应的危险因素。

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验